PharmaShots Weekly Snapshots (October 31 – November 04, 2022)
Published: Nov 04, 2022 | Tags: Pfizer, BioNTech, Omicron BA.4/BA.5-Adapted Bivalent Booster, P-II/III Trial
Published: Nov 04, 2022 | Tags: AstraZeneca, Sanofi, Beyfortus, nirsevimab, RSV Lower Respiratory Tract Disease, Regulatory, EC, Approval
Published: Nov 04, 2022 | Tags: Pfizer, BioNTech, mRNA-Based Combination Vaccine, COVID-19, Influenza, P-I Study
Published: Nov 04, 2022 | Tags: Ascentage Pharma, Lisaftoclax, APG-2575, acalabrutinib, lisaftoclax, rituximab, Chronic Lymphocytic Leukemia, ASH, 2022, Clinical Trial
Published: Nov 04, 2022 | Tags: Pfizer, Elranatamab, Multiple Myeloma, Regulatory, US, FDA, Breakthrough Therapy Designation
Exelixis Entered into New License Agreement with Catalent for Three Antibody-Drug Conjugate Programs
Published: Nov 04, 2022 | Tags: Exelixis, Catalent, Antibody-Drug Conjugate Programs, SMARTag bioconjugation platform, License Agreement, Biotech
Published: Nov 03, 2022 | Tags: REGENXBIO, RGX-314, Diabetic Retinopathy, Suprachoroidal Delivery. 55th Annual Retina Society Meeting, Clinical Trial, P-II ALTITUDE Trial
Published: Nov 03, 2022 | Tags: Hansa, Sarepta, Imlifidase, SRP-9001, Duchenne Muscular Dystrophy, Clinical Trial
Published: Nov 03, 2022 | Tags: Rigel, Fostamatinib, COVID-19, Clinical Trial, P-III, FOCUS Trial
Published: Nov 03, 2022| Tags: Gilead, Vemlidy, tenofovir alafenamide, Chronic Hepatitis B Virus Infection, Regulatory, sNDA, US, FDA, Approval
Published: Nov 03, 2022 | Tags: IGM Biosciences, ADC, Imvotamab, IGM-2323, Zynlonta, B Cell Non-Hodgkin’s Lymphoma, P-I Study, Pharma
Arcturus Collaborated with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Published: Nov 03, 2022 | Tags: Arcturus, CSL, Self-amplifying mRNA Vaccines, LUNAR delivery platform technologies, COVID-19, influenza, Biotech
Published: Nov 02, 2022 | Tags: BeiGene, Brukinsa, zanubrutinib, Marginal Zone Lymphoma, Regulatory, EC, Approval
Published: Nov 02, 2022 | Tags: Rhythm, Setmelanotide, Hypothalamic Obesity, Regulatory, US, FDA, Breakthrough Therapy Designation
Published: Nov 02, 2022 | Tags: Henlius, Hansizhuang, serplulimab, Non-Small Cell Lung Cancer, Regulatory, NMPA, Approval
Published: Nov 02, 2022 | Tags: Exelixis, Sairopa, ADU-1805, Cancer, Clinical Development, Option Agreement, Pharma
Published: Nov 02, 2022 | Tags: Exelixis, Cybrexa, CBX-12, alphalex exatecan, Solid Tumors, Pharma
Johnson & Johnson to Acquire Abiomed for ~$16.6B
Published: Nov 02, 2022 | Tags: Johnson & Johnson, Abiomed, ~$16.6B, Heart Failure, Acquire, M&A
Published: Nov 01, 2022 | Tags: Pfizer, RSVpreF, Respiratory Syncytial Virus, Clinical Trial, P-III MATISSE Trial
Published: Nov 01, 2022 | Tags: Memo Therapeutics AG, Ono, Antibodies, Immuno-Oncology Targets, infectious diseases, Pharma
Published: Nov 01, 2022 | Tags: Dyne Therapeutics, DYNE-251, Duchenne Muscular Dystrophy, Regulatory, US, FDA, Fast Track Designation
Published: Nov 01, 2022 | Tags: Bioscytogen, ISU ABXIS, Tri-specific Antibodies, YH003, pancreatic ductal adenocarcinoma and melanoma, Biotech
Published: Nov 01, 2022 | Tags: Antengene, ATG-017, Advanced Solid Tumors, Regulatory, P-I, ERASER Trial, US FDA, IND
Published: Nov 01, 2022 | Tags: Ascendis Pharma, TransCon PTH, Hypoparathyroidism, regulatory, US, FDA, NDA, Priority Review
Published: Oct 31, 2022 | Tags: Bristol Myers Squibb, Reblozyl, luspatercept-aamt, Myelodysplastic Syndromes, Clinical Trial, P-III COMMANDS Study
Published: Oct 31, 2022 | Tags: Innovent, IBI343, Advanced Solid Tumors, Clinical Trials, P-I Study
Outlook Therapeutics Reports the US FDA Acceptance of BLA for ONS-5010 to Treat Wet AMD
Published: Oct 31, 2022 | Tags: Outlook Therapeutics, ONS-5010, Wet AMD, Regulatory, US, FDA, BLA
CytoDyn Reports the Withdrawal of BLA for Leronlimab to Treat HIV
Published: Oct 31, 2022 | Tags: CytoDyn, Leronlimab, HIV, Clinical Trials, Withdrawal, BLA, HIV-MDR
Published: Oct 31, 2022 | Tags: AbbVie, Epcoritamab, Diffuse Large B-Cell Lymphoma, Large B-Cell Lymphoma, Regulatory, EMA, MAA
Published: Oct 31, 2022 | Tags: Roche, Actemra IV, tocilizumab, COVID-19, Regulatory, Health Canada
Related Post: PharmaShots Weekly Snapshots (October 24 - 28, 2022)
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.